Search

A major side effect of anti-neoplastic immunotherapy is the onset of dermatologic toxicities following the administration of several different immunotherapy drugs. We sought to assess the incidence and mortality of anti-neoplastic immunotherapy-associated dermatologic toxicities using a nationally representative sample of United States (US) adults. The National Inpatient Sample database was queried for encounters undergoing anti-neoplastic immunotherapy. Multiple logistic regression models were constructed to analyze incidence of dermatologic toxicity and associated mortality as well as calculate adjusted odds ratios (aOR) after controlling for age, race, sex, household income, and cancer type. Immunotherapy patients demonstrated greater odds of developing pruritus (aOR = 7.59; 95% CI 5.17–11.2; P < 0.001), rash (aOR = 2.81; 95% CI 2.00–3.94, P < 0.001), generalized (aOR = 5.32; 95% CI 3.35–8.43; P < 0.001) and localized (aOR = 2.67; 95% CI 1.01–7.05; P < 0.001) skin eruptions, and vitiligo (aOR = 13.3; 95% CI 5.15–34.4; P < 0.001) compared to patients who did not receive anti-neoplastic immunotherapy. There were no significant differences observed in incidence of non-scarring alopecia (P = 0.7), psoriasis (P = 0.094), and dermatitis (P = 0.9) between the two groups. Patients who underwent immunotherapy were more likely to develop dermatologic toxicity (aOR = 3.93; 95% CI 3.12–4.94; P < 0.001), however, no significant differences in mortality were observed. Patients undergoing anti-neoplastic immunotherapy have an increased risk of developing dermatologic toxicity compared to patients who did not receive anti-neoplastic immunotherapy. [ABSTRACT FROM AUTHOR]

Patients with disabilities utilize accommodations or assistive technologies to access content from healthcare websites, but not all websites are built accessibly. We sought to evaluate the accessibility of dermatology home page websites from the 3 largest hospitals in each state of the United States (n = 150) using evaluation tools SortSite 6.42.924.0 and the Web Accessibility Evaluation Tool (WAVE). Of 150 hospitals evaluated, 128 (85%) were teaching hospitals and 48 (32%) were from the southern United States. The average numbers of contrast errors and all other errors detected by WAVE were 13.6 and 8.9, respectively. The mean number of Level A, AA and AAA issues detected per WCAG 2.1 guidelines were 5.7, 1.5, and 2.5, respectively. There were no significant differences in any accessibility metrics between teaching and non-teaching hospitals. Overall, dermatology home page websites have an average of 6 failures to meet the baseline A criteria of WCAG 2.1 and no websites were completely adherent to standards. The mean elements of contrast errors, other errors, alerts, and structural elements issues were all greater in the dermatology websites than in a federal public health website in a global analysis. Inaccessible dermatology websites present a significant barrier for patients to schedule and receive dermatologic care at hospitals nationally and may result in adverse outcomes for this underserved population. Dermatologic care teams and web developers must prioritize improving the accessibility of their websites to benefit all patients. [ABSTRACT FROM AUTHOR]

The article offers information on the multiscale modeling framework (MMF) for parameterizing convective clouds and cloud systems by the U.S. National Aeronotics and Space Administration (NASA), Goddard Space Flight Center (GSFC). The Goddard finite-volume MMF is based on the NASA Goddard finite-volume Generic Circulation Model (GCM) and the Goddard Cumulus Ensemble model (GCE). The Goddard MMF has been evaluated against observations at interannual, intraseasonal, and diurnal time scales using a two year long simulation representing different climate scenarios. MMFs can bridge the gap between traditional Cloud Resolving Models (CRM) simulations, regional weather forecast models, and current and future non hydrostatic global cloud-resolution models.

The Coordinated Enhanced Observing Period (CEOP) is an international project that was first proposed by the Global Energy and Water Cycle Experiment (GEWEX) in 1997 and was formally launched in 2001. Since that time it has been adopted by the World Climate Research Programme (WCRP), which views it as an essential part of its strategy for developing global datasets to evaluate global climate models, and by the Integrated Global Observing Strategy Partnership (IGOS-P), which views it as the first element of its global water cycle theme. The United States has been an active partner in all phases of CEOP. In particular, the United States has taken the lead in contributing data from a number of reference sites, providing data processing, and archiving capabilities and related research activities through the GEWEX Americas Prediction Project (GAPP). Other U.S. programs and agencies are providing components including model and data assimilation output, satellite data, and other services. The U.S. science community has also been using the CEOP database in model evaluation and phenomenological studies. This article summarizes the U.S. contributions during the first phase of CEOP and outlines opportunities for readers to become involved in the data analysis phase of the project. [ABSTRACT FROM AUTHOR]

Competing Interests: Conflicts of interest The authors declare no conflicts of interest. W.C.L. and K.Y. share first authorship.

The Research, Condition, and Disease Categorization (RCDC) project was created to standardize budget reporting by research topic. Text mining techniques have been implemented to classify NIH grant applications into proper research and disease categories. A best-fit model is shown to achieve classification performance rivaling that of concept vectors produced by human experts.